Chapter 33 Botanical Medicine—A Modern Perspective
Introduction
For many people of the world, herbal medicines are the only therapeutic agents available. In the late 1990s, the World Health Organization estimated that about 80% of the world’s population relies on herbs for primary health care needs.1 This widespread use of herbal medicines is not restricted to developing countries, since it has been estimated that 70% of all medical doctors in France and Germany regularly prescribe herbal preparations.
Throughout the world, but especially in Europe, the United States, Canada, Australia, and Japan, a tremendous renaissance in the use and appreciation of herbal medicine occurred in the latter part of the twentieth century. For example, in the United States, the sale of herbal products skyrocketed from $200 million in 1988 to more than $3.5 billion in 1997 before leveling off in the $4 billion a year range (Table 33-1). Within the European Community annual sales exceeded $7 billion in 1997.2
YEAR | $ TOTAL SALES (MILLIONS) | % INCREASE (-DECREASE) |
---|---|---|
1994 | 2020 | |
1995 | 2470 | 22.3 |
1996 | 2990 | 21.1 |
1997 | 3557 | 19.0 |
1998 | 4002 | 12.5 |
1999 | 4110 | 2.7 |
2000 | 4260 | 3.7 |
2001 | 4397 | 3.2 |
2002 | 4276 | −2.8 |
2003 | 4178 | −2.3 |
2004 | 4320 | 3.4 |
2005 | 4410 | 2.1 |
Data from Ferrier GKL, Thwaites LA, Rea PR, et al. U.S. consumer herbal and herbal botanical supplement sales. Nutr Business J. 2006. http://www.nutritionbusiness.com.
The Role of Herbs in Modern Pharmacy
Plants still play a major role in modern pharmacy. For the past 50 years, about 25% of all prescription drugs in the United States and other developed countries have contained active constituents obtained from plants. Digoxin, codeine, colchicine, morphine, vincristine, and yohimbine are some popular examples. Many over-the-counter (OTC) preparations are also composed of plant compounds. Pharmacognosy, the study of natural drugs and their constituents, plays a major role in current drug development. Unfortunately, the standard path of the approval of a drug is a process that typically takes 10 to 18 years at a total cost of roughly $250 million (Table 33-2).
DRUG | CLINICAL USE | BOTANICAL SOURCE |
---|---|---|
Atropine | Anticholinergic | Atropa belladonna |
Caffeine | Central nervous system stimulant | Cola nitida |
Camphor | Rubefacient | Cinnamomum camphora |
Cocaine | Local anesthetic | Erythroxylon coca |
Codeine | Analgesic/antitussive | Papaver somniferum |
Colchicine | Antigout | Colchicum autumnale |
Digitoxin | Cardiotonic | Digitalis purpurea |
Digoxin | Cardiotonic | Digitalis lanata |
Emetine | Amebicide/emetic | Cephaelis ipecacuanha |
Ephedrine | Sympathomimetic | Ephedra sinica |
Gossypol | Male contraceptive | Gossypium spp. |
Hyoscyamine | Anticholinergic | Hyoscyamus niger |
Kawain | Tranquilizer | Piper methysticum |
Methoxsalen | Psoriasis/vitiligo | Ammi majus |
Morphine | Analgesic | Papaver somniferum |
Noscapine | Antitussive | Papaver somniferum |
Physostigmine | Cholinesterase inhibitor | Physostigma venenosum |
Pilocarpine | Parasympathomimetic | Pilocarpus jaborandi |
Podophyllotoxin | Topical wart remedy | Podophyllum peltatum |
Quabain | Cardiotonic | Strophanthus gratus |
Quinine | Antimalarial | Cinchona ledgeriana |
Reserpine | Antihypertensive | Rauwolfia serpentine |
Scopolamine | Sedative | Datura metel |
Sennosides | Laxative | Cassia spp. |
Theophylline | Bronchodilator | Camellia sinensis |
Tubocurarine | Muscle relaxant | Chondrodendron tomentosum |
Yohimbine | Male erectile dysfunction | Pausinystalia yohimbe |
Data from De Smet PA. Drugs 1997;54:801-840.
Because a plant cannot be patented, plants are screened for biological activity and then the so-called “active” constituents (compounds) are isolated and typically chemically modified to produce unique substances. If the compound is powerful enough, the drug company begins the process to procure Food and Drug Administration (FDA) approval. Of 520 new drugs approved by the FDA or comparable entities in developed countries, 30 came directly from natural product sources and another 173 were either semisynthetic from a natural source or modeled after a naturally occurring compound.1
Because of the expense and lack of patent protection, few clinical evaluations were done before 1980 on whole plants or crude plant extracts as medicinal agents per se. A key factor in contributing to more research into herbal medicines after this time was the development in Europe of regulatory policies and practices that made it economically feasible for companies to do research. For example, in Germany, regulations allow herbal products to be marketed with drug claims if they are proven to be safe and effective.3 Whether the herbal product is available by prescription or OTC is based on its application and safety of use. Herbal products sold in pharmacies are reimbursed by insurance if they are prescribed by a physician.